

Advanced Solid Tumors Metastatic Solid Tumors

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Trial Status
Recruiting

Trial Runs In
3 Countries

Trial Identifier
NCT06537310 2024-512839-70-00
BP44956

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is not acceptable to the participant.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT06537310 2024-512839-70-00 BP44956
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
